{"id":69495,"date":"2026-07-07T14:28:36","date_gmt":"2026-07-07T06:28:36","guid":{"rendered":"https:\/\/flcube.com\/?p=69495"},"modified":"2026-07-07T14:28:36","modified_gmt":"2026-07-07T06:28:36","slug":"campfield-therapeutics-launches-with-180m-series-a-to-advance-prifemilast-pde4-inhibitor-for-ibd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69495","title":{"rendered":"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>cAMPfield Therapeutics, Inc.<\/strong> announced its <strong>official launch<\/strong> alongside the completion of a <strong>$180 million Series A financing round<\/strong>, establishing the company as a new player in inflammatory disease therapeutics with lead asset <strong>prifemilast (HY1999\/HPP737)<\/strong>, a <strong>once-daily oral PDE4 inhibitor<\/strong> for <strong>inflammatory bowel disease (IBD)<\/strong> treatment.<\/p>\n\n\n\n<h2 id=\"h-financing-structure-amp-investor-consortium\" class=\"wp-block-heading\">Financing Structure &amp; Investor Consortium<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company Status<\/strong><\/td><td>Newly launched biotechnology company<\/td><\/tr><tr><td><strong>Financing Round<\/strong><\/td><td>Series A<\/td><\/tr><tr><td><strong>Amount Raised<\/strong><\/td><td>USD 180 million<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Frazier Life Sciences<\/td><\/tr><tr><td><strong>Participating Investors<\/strong><\/td><td>Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, RA Capital<\/td><\/tr><tr><td><strong>Investor Profile<\/strong><\/td><td>Premier life sciences investment firms with combined assets under management exceeding $15 billion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-amp-development-strategy\" class=\"wp-block-heading\">Asset Profile &amp; Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Product:<\/strong> <strong>Prifemilast (HY1999\/HPP737)<\/strong> \u2013 investigational, <strong>once-daily oral PDE4B-selective inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>Inflammatory bowel disease (IBD)<\/strong> \u2013 encompassing Crohn&#8217;s disease and ulcerative colitis<\/li>\n\n\n\n<li><strong>Mechanism Advantage:<\/strong> PDE4B selectivity potentially offers improved safety profile compared to pan-PDE4 inhibitors, which have historically been limited by gastrointestinal side effects<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Advancing toward late-stage clinical development with global rights secured<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-corporate-evolution-amp-rights-transfer\" class=\"wp-block-heading\">Corporate Evolution &amp; Rights Transfer<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Transaction Timeline<\/th><th>Parties Involved<\/th><th>Rights Scope<\/th><\/tr><\/thead><tbody><tr><td><strong>2018<\/strong><\/td><td>Newsoara Biopharma + vTv Therapeutics<\/td><td>China and Pacific Rim development\/commercialization rights<\/td><\/tr><tr><td><strong>February 2026<\/strong><\/td><td>Newsoara Biopharma + vTv Therapeutics<\/td><td>Expanded to <strong>global rights<\/strong><\/td><\/tr><tr><td><strong>June 2026<\/strong><\/td><td>Newsoara Biopharma \u2192 cAMPfield Therapeutics<\/td><td><strong>Global rights transferred<\/strong> to newly formed cAMPfield<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction represents a strategic spin-out of prifemilast into a dedicated company with specialized focus and substantial capital backing, enabling accelerated global development.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IBD Market Size:<\/strong> Global IBD therapeutics market valued at $22 billion in 2025, projected to reach $35 billion by 2030<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Despite biologic dominance, 30-40% of patients fail to respond adequately or lose response over time, creating demand for novel oral small molecule approaches<\/li>\n\n\n\n<li><strong>PDE4 Inhibitor Precedent:<\/strong> Otezla (apremilast) demonstrated commercial success in psoriasis\/psoriatic arthritis ($2.9 billion annual sales), validating PDE4 inhibition as a viable therapeutic approach<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Once-daily dosing and PDE4B selectivity may address compliance and tolerability limitations that have hampered previous PDE4 inhibitors in IBD<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-investment-thesis\" class=\"wp-block-heading\">Strategic Rationale &amp; Investment Thesis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Strategic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Investor Consortium<\/strong><\/td><td>Access to late-stage IBD asset with established safety data and clear regulatory pathway; opportunity to build focused IBD franchise<\/td><\/tr><tr><td><strong>Newsoara Biopharma<\/strong><\/td><td>Monetizes global asset while retaining potential milestone\/royalty participation; focuses resources on core China\/Pacific Rim pipeline<\/td><\/tr><tr><td><strong>cAMPfield Therapeutics<\/strong><\/td><td>Clean corporate structure with dedicated management team; substantial capital runway for pivotal trials and commercial preparation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding cAMPfield Therapeutics&#8217; launch, financing, clinical development plans, and commercial prospects for prifemilast. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive developments, and market dynamics in the IBD therapeutic landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[65,4837],"class_list":["post-69495","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-campfield-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series A financing round, establishing the company as a new player in inflammatory disease therapeutics with lead asset prifemilast (HY1999\/HPP737), a once-daily oral PDE4 inhibitor for inflammatory bowel disease (IBD) treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69495\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD\" \/>\n<meta property=\"og:description\" content=\"cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series A financing round, establishing the company as a new player in inflammatory disease therapeutics with lead asset prifemilast (HY1999\/HPP737), a once-daily oral PDE4 inhibitor for inflammatory bowel disease (IBD) treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69495\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T06:28:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69495#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69495\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD\",\"datePublished\":\"2026-07-07T06:28:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69495\"},\"wordCount\":446,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"cAMPfield Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69495#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69495\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69495\",\"name\":\"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-07T06:28:36+00:00\",\"description\":\"cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series A financing round, establishing the company as a new player in inflammatory disease therapeutics with lead asset prifemilast (HY1999\\\/HPP737), a once-daily oral PDE4 inhibitor for inflammatory bowel disease (IBD) treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69495#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69495\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69495#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD - Insight, China&#039;s Pharmaceutical Industry","description":"cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series A financing round, establishing the company as a new player in inflammatory disease therapeutics with lead asset prifemilast (HY1999\/HPP737), a once-daily oral PDE4 inhibitor for inflammatory bowel disease (IBD) treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69495","og_locale":"en_US","og_type":"article","og_title":"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD","og_description":"cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series A financing round, establishing the company as a new player in inflammatory disease therapeutics with lead asset prifemilast (HY1999\/HPP737), a once-daily oral PDE4 inhibitor for inflammatory bowel disease (IBD) treatment.","og_url":"https:\/\/flcube.com\/?p=69495","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T06:28:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69495#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69495"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD","datePublished":"2026-07-07T06:28:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69495"},"wordCount":446,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","cAMPfield Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69495#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69495","url":"https:\/\/flcube.com\/?p=69495","name":"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-07T06:28:36+00:00","description":"cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series A financing round, establishing the company as a new player in inflammatory disease therapeutics with lead asset prifemilast (HY1999\/HPP737), a once-daily oral PDE4 inhibitor for inflammatory bowel disease (IBD) treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69495#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69495"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69495#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69495"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69495\/revisions"}],"predecessor-version":[{"id":69498,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69495\/revisions\/69498"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}